How Pharmaceutical Companies Delay Generic Drug Access in Europe
March 28, 2025 · Frisian News
European pharmaceutical giants use legal tactics and patent strategies to block cheaper generic versions of drugs from reaching patients. Health authorities struggle to enforce timely access as companies exploit loopholes in European regulations.
Regulators blocked a generic version of a common heart drug because the original patent holder filed a last-minute complaint about labeling. The drug works identically to the brand name version. It costs significantly less. Yet patients wait months for access, and the pharmaceutical company gets more months of monopoly sales. This scene repeats across Europe every week.
Pharmaceutical firms deploy a strategy called 'evergreening' to keep generics off shelves. They make small changes to drug formulations, apply new patents, extend exclusivity periods, or file legal challenges to generic approvals just before they take effect. European patent law gives these companies multiple opportunities to obstruct. Patent offices across European capitals process hundreds of these blocking actions annually. Few national governments have the resources to fight them quickly.
The cost falls on patients and taxpayers. Generic drugs cost 80 to 90 percent less than originals. When companies delay generics by two or three years, European health systems spend billions in unnecessary expenses. Smaller countries face even sharper budget pressures. Hospitals ration treatments, cut staff, or defer equipment purchases because generic prices never arrive as fast as they should.
European Union regulators know this happens. The European Medicines Agency and national health authorities have flagged the problem in reports dating back a decade. Yet Brussels has refused to tighten timelines or impose penalties for frivolous patent claims. Pharmaceutical lobbies influence policy. These companies employ hundreds of lawyers and spend millions on political access. Small patient groups and generic manufacturers lack the same firepower. The system works exactly as the strongest side designed it.
Generic manufacturers and health advocates push for faster review processes and penalties for abuse. Some nations have tested accelerated approval paths with modest success. The real fix requires political will: governments must decide whether they serve patients or corporations. So far, across Europe, the answer remains unclear.
Published March 28, 2025 · Frisian News